|
시장보고서
상품코드
2091744
뎅기열 백신 시장 규모, 점유율 및 성장 분석 : 백신 유형별, 적응증별, 연령층별, 최종사용자별, 유통 채널별, 투여 스케줄별, 지역별 - 업계 예측(2026-2033년)Dengue Vaccines Market Size, Share, and Growth Analysis, By Vaccine Type, By Indication, By Age Group, By End User, By Distribution Channel, By Dosage Schedule, By Region - Industry Forecast 2026-2033 |
||||||
세계의 뎅기열 백신 시장 규모는 2024년에 4억 2,318만 달러로 평가되며, 2025년 4억 8,116만 달러에서 2033년까지 13억 4,391만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 13.7%로 성장할 것으로 전망되고 있습니다.
열대 지역의 모기 개체 수 증가와 효과적인 예방책의 필요성으로 인해 전 세계 뎅기열 백신 시장의 수요가 증가하고 있습니다. 특히 동남아시아와 라틴아메리카에서는 각국 정부가 뎅기열 유행 대책의 일환으로 백신 접종을 국가의 최우선 과제 중 하나로 삼고 있습니다. 다케다 제약이나 사노피 파스퇴르와 같은 주요 기업이 자사 백신으로 시장을 주도하는 한편, 지속적인 연구와 제휴를 통해 혁신을 촉진하고 신제품에 대한 접근성을 확대하고 있습니다. 뎅기열 발생 건수가 증가하는 데다, 민간 백신 접종에 투자하려는 의지가 있는 중산층이 확대됨에 따라 각 제약사는 단계적인 가격 책정 전략을 채택하고 있습니다. 이러한 환경은 브라질이나 인도와 같은 뎅기열 유행국에서 현지 생산의 가능성을 넓히고, 수입 의존도를 낮추며, 백신 접종률을 높임으로써 공중보건과 경제 안정에 기여하게 될 것입니다.
세계 뎅기열 백신 시장의 성장 요인
전 세계 뎅기열 백신 시장은 네타이시마카 모기에게 이상적인 번식지가 되는 도시 지역의 확장에 힘입어 크게 성장하고 있으며, 이로 인해 뎅기열 유행이 급증하고 있습니다. 이러한 증가 추세를 감안하여, 규제 당국은 국민 사이에서 뎅기열 바이러스 감염 발생을 억제하기 위한 예방 전략을 추진하는 노력을 더욱 강화하고 있습니다. 또한 질병 예방의 중요성에 대한 일반 시민들의 인식이 높아짐에 따라 효과적인 백신 솔루션에 대한 수요가 확대되고 있습니다. 이러한 공중보건상의 시급한 과제에 대응하기 위해 각 제약사들은 뎅기열 백신 개발 및 공급에 대한 투자에 적극적으로 나서고 있으며, 이는 시장 성장을 더욱 촉진하고 있습니다. 또한 각국 정부도 백신 접종 프로그램에 자원을 할당하는 경향을 보이고 있으며, 뎅기열 백신 분야의 밝은 전망을 더욱 공고히 하고 있습니다.
세계 뎅기열 백신 시장의 제약 요인
전 세계 뎅기열 백신 시장은 지역별 문화적 신념, 잘못된 정보, 부족한 건강 문해력의 영향으로 인해 백신 수용도가 지역에 따라 달라지는 바람에 큰 제약에 직면해 있습니다. 회의적인 태도가 나타나는 지역에서 백신 접종을 촉진하기 위한 공중보건 정책은 수많은 과제에 직면해 있으며, 광범위한 예방접종 실현을 위한 노력을 저해하고 백신 시장의 확대를 제한하고 있습니다. 이처럼 낮은 접종률은 수요가 저조한 상태이기 때문에 제조사들이 해당 지역에 대한 투자를 주저하게 만드는 요인이 되며, 결국 시장의 성장을 저해하게 됩니다. 또한 규제 당국은 수요가 낮은 지역에서 시판 후 모니터링 요건을 더욱 엄격하게 적용할 가능성이 있으며, 이로 인해 백신 유통 비용이 더욱 상승하고, 기업이 해당 시장에서 상당한 판매량을 달성할 가능성이 낮아지게 될 것입니다.
세계 뎅기열 백신 시장의 동향
세계 뎅기열 백신 시장은 재조합 기술의 발전에 힘입어 획기적인 변화를 겪고 있습니다. 이러한 혁신적인 플랫폼은 면역원성을 높이는 동시에 반응원성 반응을 최소화함으로써, 다양한 신종 뎅기열 바이러스 혈청형에 대한 백신 개발을 가능하게 하고 있습니다. 과거 백신 개발 과정에서 축적된 지식을 활용함으로써, 제약사는 시장 출시까지의 기간을 단축하고, 의료 종사자들의 우려를 해소함으로써 더 높은 수용률을 확보할 수 있습니다. 이러한 세계적 규제 기준을 충족함으로써, 더 광범위한 시장 접근이 촉진되고, 뎅기열 백신이 유행하는 지역에 널리 보급될 수 있게 됩니다. 결국, 이러한 추세는 뎅기열 유행 대응을 목표로 하는 전 세계 공중보건 구상의 포괄적인 목표를 지원하게 될 것입니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 뎅기열 백신 시장 규모 : 백신 유형별
세계의 뎅기열 백신 시장 규모 : 적응증별
세계의 뎅기열 백신 시장 규모 : 연령층별
세계의 뎅기열 백신 시장 규모 : 최종사용자별
세계의 뎅기열 백신 시장 규모 : 유통 채널별
세계의 뎅기열 백신 시장 규모 : 투여 스케줄별
세계의 뎅기열 백신 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSA 26.07.22Global Dengue Vaccines Market size was valued at USD 423.18 Million in 2024 and is poised to grow from USD 481.16 Million in 2025 to USD 1343.91 Million by 2033, growing at a CAGR of 13.7% during the forecast period (2026-2033).
The global dengue vaccine market is witnessing heightened demand due to rising mosquito populations in tropical regions and the need for effective preventative measures. Governments are designating vaccinations as critical national priorities to combat outbreaks of dengue fever, particularly in Southeast Asia and Latin America. Major players like Takeda and Sanofi-Pasteur are leading the market with their vaccines, while ongoing research and partnerships are driving innovation and making new products more accessible. The increased incidences of dengue, alongside a growing middle class willing to invest in private vaccinations, is prompting manufacturers to adopt tiered pricing strategies. This environment opens avenues for local production in dengue-endemic countries like Brazil and India, reducing reliance on imports and enhancing vaccination uptake, thereby benefiting public health and economic stability.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Dengue Vaccines market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Dengue Vaccines Market Segments Analysis
Global dengue vaccines market is segmented by vaccine type, indication, age group, end user, distribution channel, dosage schedule and region. Based on vaccine type, the market is segmented into live attenuated vaccines, recombinant vaccines and other vaccine technologies. Based on indication, the market is segmented into primary dengue prevention and secondary dengue prevention. Based on age group, the market is segmented into pediatric population and adult population. Based on end user, the market is segmented into hospitals, vaccination centers, public health programs and others. Based on distribution channel, the market is segmented into government procurement, hospital pharmacies, retail pharmacies and others. Based on dosage schedule, the market is segmented into single-dose vaccines and multi-dose vaccines. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Dengue Vaccines Market
The global dengue vaccine market is significantly driven by the proliferation of urban areas, which serve as ideal breeding grounds for Aedes mosquitoes, leading to a surge in dengue outbreaks. In light of this rising trend, regulatory authorities have increasingly implemented initiatives to promote preventive strategies aimed at curbing the incidence of dengue virus infections in their populations. Moreover, the growing public awareness around the importance of disease prevention has spurred heightened demand for effective vaccination solutions. In response to this public health imperative, pharmaceutical companies are more inclined to invest in the development and distribution of dengue vaccines, further propelling the market's growth. Additionally, governments are likely to allocate resources towards vaccination programs, reinforcing the positive outlook for the dengue vaccine sector.
Restraints in the Global Dengue Vaccines Market
The Global Dengue Vaccines market faces significant constraints due to varying levels of vaccine acceptance influenced by cultural beliefs, misinformation, and inadequate health literacy across different regions. Public health initiatives aimed at promoting vaccination in areas with skepticism encounter numerous challenges, hindering efforts to achieve widespread immunization and restricting the vaccine market's reach. This limited uptake discourages manufacturers from investing in these regions, as demand remains low, ultimately stifling market growth. Moreover, regulatory bodies may impose more strict post-marketing surveillance requirements in low-demand areas, further elevating costs for vaccine distribution and diminishing the potential for companies to achieve substantial sales volumes in these markets.
Market Trends of the Global Dengue Vaccines Market
The Global Dengue Vaccines market is experiencing a transformative shift driven by advancements in recombinant technologies. These innovative platforms enhance immunogenicity while minimizing reactogenic responses, enabling the development of vaccines against a diverse array of emerging dengue virus serotypes. By leveraging established knowledge from prior vaccine development, manufacturers can accelerate the time to market and address healthcare provider concerns, ensuring higher acceptance rates. This alignment with global regulatory standards facilitates broader market access, positioning dengue vaccines for widespread implementation in endemic regions. Ultimately, this trend supports the overarching goals of global public health initiatives aimed at combating dengue outbreaks.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Dengue Vaccines Market Size by Vaccine Type & CAGR (2026-2033)
- Market Overview
- Live Attenuated Vaccines
- Recombinant Vaccines
- Other Vaccine Technologies
Global Dengue Vaccines Market Size by Indication & CAGR (2026-2033)
- Market Overview
- Primary Dengue Prevention
- Secondary Dengue Prevention
Global Dengue Vaccines Market Size by Age Group & CAGR (2026-2033)
- Market Overview
- Pediatric Population
- Adult Population
Global Dengue Vaccines Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Vaccination Centers
- Public Health Programs
- Others
Global Dengue Vaccines Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Government Procurement
- Hospital Pharmacies
- Retail Pharmacies
- Others
Global Dengue Vaccines Market Size by Dosage Schedule & CAGR (2026-2033)
- Market Overview
- Single-Dose Vaccines
- Multi-Dose Vaccines
Global Dengue Vaccines Market Size & CAGR (2026-2033)
- North America (Vaccine Type, Indication, Age Group, End User, Distribution Channel, Dosage Schedule)
- US
- Canada
- Europe (Vaccine Type, Indication, Age Group, End User, Distribution Channel, Dosage Schedule)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Vaccine Type, Indication, Age Group, End User, Distribution Channel, Dosage Schedule)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Vaccine Type, Indication, Age Group, End User, Distribution Channel, Dosage Schedule)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Vaccine Type, Indication, Age Group, End User, Distribution Channel, Dosage Schedule)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Moderna, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- BioNTech SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Butantan Institute
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Panacea Biotec Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Serum Institute of India Pvt. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bharat Biotech International Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biological E. Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Emergent BioSolutions Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Valneva SE
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- SK bioscience Co., Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Intravacc B.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Codagenix, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Themis Bioscience GmbH
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Vabiotech
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
